Update on medicines for smoking cessation
- PMID: 26648633
- PMCID: PMC4653977
- DOI: 10.18773/austprescr.2015.038
Update on medicines for smoking cessation
Abstract
Persistent cigarette smokers usually have a nicotine addiction. This addiction has a chronic relapsing and sometimes remitting course and may persist lifelong. Remission can be facilitated by the use of medication as part of a comprehensive management strategy tailored to the individual patient. Nicotine replacement therapy is a first-line drug treatment. It is available in many formulations. Varenicline is also a first-line drug treatment. It should be started before the patient stops smoking. Bupropion is a second-line therapy. It may be associated with an increased risk of seizures and drug interactions. While there is some evidence that electronic cigarettes might facilitate smoking cessation, quit rates are not yet comparable with those of the drugs approved on the Pharmaceutical Benefits Scheme.
Keywords: bupropion; nicotine; smoking cessation; varenicline.
Conflict of interest statement
Conflict of interest: none declared
References
-
- McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95. - PubMed
-
- Australian Bureau of Statistics. 4364.0.55.003 - Australian Health Survey: Updated Results, 2011-2012. Canberra: ABS; 2013 June. www.abs.gov.au/ausstats/abs@.nsf/Lookup/4364.0.55.003Chapter12011-2012 [cited 2015 Jul 1]
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources